Healthcare provider profile · identity verified

Geoffrey Robert Hamilton, MD

Internal Medicine · BRISTOL, RI · NPI 1467453431

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	530	136
Lisinopril	Lisinopril	400	104
Amlodipine Besylate	Amlodipine Besylate	315	76
Omeprazole	Omeprazole	274	84
Levothyroxine Sodium	Levothyroxine Sodium	273	56
Losartan Potassium	Losartan Potassium	261	73
Gabapentin	Gabapentin	172	35
Citalopram Hbr	Citalopram Hydrobromide	162	39
Hydrochlorothiazide	Hydrochlorothiazide	160	42
Prednisone	Prednisone	158	97
Eliquis	Apixaban	146	32
Tamsulosin Hcl	Tamsulosin Hcl	137	36
Simvastatin	Simvastatin	127	30
Meloxicam	Meloxicam	111	27
Azithromycin	Azithromycin	110	89
Albuterol Sulfate Hfa	Albuterol Sulfate	109	38
Escitalopram Oxalate	Escitalopram Oxalate	106	24
Clonazepam	Clonazepam	105	19
Furosemide	Furosemide	105	30
Lovastatin	Lovastatin	95	25
Allopurinol	Allopurinol	94	23
Alprazolam	Alprazolam	93	28
Metoprolol Succinate	Metoprolol Succinate	89	29
Trazodone Hcl	Trazodone Hcl	87	21
Metformin Hcl	Metformin Hcl	84	27
Tramadol Hcl	Tramadol Hcl	78	23
Ozempic	Semaglutide	71	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	68	20
Famotidine	Famotidine	63	15
Metoprolol Tartrate	Metoprolol Tartrate	63	19
Alendronate Sodium	Alendronate Sodium	62	13
Sertraline Hcl	Sertraline Hcl	62	18
Atenolol	Atenolol	60	16
Fluticasone Propionate	Fluticasone Propionate	60	25
Pantoprazole Sodium	Pantoprazole Sodium	58	18
Zolpidem Tartrate	Zolpidem Tartrate	55	suppressed
Lorazepam	Lorazepam	54	14
Oxycodone Hcl	Oxycodone Hcl	54	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	49	12
Montelukast Sodium	Montelukast Sodium	48	suppressed
Glipizide	Glipizide	47	11
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	46	suppressed
Duloxetine Hcl	Duloxetine Hcl	42	suppressed
Pregabalin	Pregabalin	42	suppressed
Amoxicillin	Amoxicillin	41	38
Meclizine Hcl	Meclizine Hcl	41	16
Warfarin Sodium	Warfarin Sodium	40	suppressed
Ibuprofen	Ibuprofen	39	11
Jardiance	Empagliflozin	38	suppressed
Clotrimazole	Clotrimazole	36	18
Potassium Chloride	Potassium Chloride	35	suppressed
Bupropion Xl	Bupropion Hcl	34	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	32	suppressed
Chlorthalidone	Chlorthalidone	31	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	31	22
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	30	19
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	30	25
Pravastatin Sodium	Pravastatin Sodium	30	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	29	suppressed
Metformin Hcl Er	Metformin Hcl	29	suppressed
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Clopidogrel	Clopidogrel Bisulfate	28	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	28	26
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	27	21
Donepezil Hcl	Donepezil Hcl	27	suppressed
Glipizide Er	Glipizide	27	suppressed
Spironolactone	Spironolactone	27	suppressed
Carvedilol	Carvedilol	24	suppressed
Finasteride	Finasteride	23	suppressed
Myrbetriq	Mirabegron	23	suppressed
Ramipril	Ramipril	23	suppressed
Butalbital-Acetaminophen-Caffe	Butalb/Acetaminophen/Caffeine	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Entresto	Sacubitril/Valsartan	21	suppressed
Ketoconazole	Ketoconazole	21	suppressed
Naproxen	Naproxen	21	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	21	suppressed
Cephalexin	Cephalexin	20	20
Ezetimibe	Ezetimibe	20	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	18	suppressed
Valsartan	Valsartan	18	suppressed
Bupropion Hcl Sr	Bupropion Hcl	17	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	17	suppressed
Diazepam	Diazepam	17	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Mirtazapine	Mirtazapine	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Doxepin Hcl	Doxepin Hcl	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Sumatriptan Succinate	Sumatriptan Succinate	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	13
Valacyclovir	Valacyclovir Hcl	14	suppressed
Ventolin Hfa	Albuterol Sulfate	14	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	13	suppressed
Roflumilast	Roflumilast	13	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	12	suppressed
Gemfibrozil	Gemfibrozil	12	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	12	suppressed
Synthroid	Levothyroxine Sodium	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	12	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	12	suppressed
Buprenorphine	Buprenorphine	11	suppressed
Incruse Ellipta	Umeclidinium Bromide	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error